<DOC>
	<DOCNO>NCT01792700</DOCNO>
	<brief_summary>patient fail previous H. pylorus eradication standard triple therapy randomize two regimen : 1 , esomeprazole ( 20 mg b.i.d ) , tripotassium dicitrate bismuthate ( 300 mg q.i.d ) , metronidazole ( 500 mg t.i.d ) , tetracycline ( 500 mg q.i.d ) ( EBMT ) 2 , moxifloxacin ( 400 mg q.d . ) , esomeprazole ( 20 mg b.i.d ) , amoxicillin ( 1000 mg b.i.d . ) ( MEA ) . At four week completion eradication therapy , H. pylorus test perform 13C urea breath test ( UBT ) invasive test ( Giemsa histology , CLO test , culture ) . In patient maintain continuous H. pylorus negativity first year eradication therapy , H. pylorus status assess every year . For evaluation risk factor reinfection , gender , age , clinical diagnosis , histological atrophic gastritis intestinal metaplasia analyze .</brief_summary>
	<brief_title>Long-term Follow Helicobacter Pylori Reinfection Rate After Second-Line Treatment : Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy</brief_title>
	<detailed_description />
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Patients consider persistent H. pylorus infection 13Curea breath test ( UBT ) invasive H. pylori test ( Giemsa histology , CLO test , culture ) positive despite PPIbased triple therapy . Patients exclude study history renal hepatic impairment , previous gastric surgery , pregnancy lactation , therapy steroid nonsteroidal antiinflammatory drug , therapy proton pump inhibitor ( PPI ) antibiotic within four week entry .</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>